Metabolomics is the worldwide assessment and confirmation of endogenous small-molecule biochemicals (metabolites) within a biologic system. It is one of the "omic" sciences in systems biology. The metabolism of cancer cells is dysregulated to meet the demands of uncontrolled proliferation. This rewiring of cellular metabolism produces distinct metabolic phenotypes that can be exploited for earlier cancer detection, patient selection techniques for clinical trials, and/or treatment response biomarkers. Metabolomics aims to use cancer’s metabolic signature to estimate disease risk, detect cancer earlier, diagnose particular disease subtypes, and track treatment outcomes. In principle, metabolomics could aid in the rational selection of targeted medicines to meet cancer’s metabolic requirements.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : A case-based approach using IMPeTUs criteria in FDG PET/CT reporting of multiple myeloma
Mudalsha Ravina, All India Institute of Medical Sciences, India
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Transforming cancer care: Innovations, integrations, and impact
Shayan Maqsood, Jamia Hamdard University, India
Title : Genetic and epigenetic alterations of SOX7 in multiple myeloma and allied neoplasms
Can Küçük, Dokuz Eylul University, Turkey
Title : Advanced nanoparticles, the hallmark of targeted drug delivery for osteosarcoma
Shayan Maqsood, Jamia Hamdard University, India